Effective medical treatment for common baldness in women

Summary Endocrine profiles were established in nineteen women, aged 18–43 years, with common baldness. Reduced plasma levels were found in SHBG (68%), luteal phase progesterone (52%) indicating sub‐fertility, LH (42%), oestradiol (37%) and FSH (21%), while plasma total testosterone was raised in only one patient. Three women with a history of diffuse loss of scalp hair of 2, 13 and 23 years duration and a familial history of premature balding in two, were treated with cyclical antiandrogen therapy (CAT) for 52 weeks. All showed an increase in hair density (hairs/cm2), and in the number of hairs greater than 40 um diameter/cm2 (meaningful density) after 24–28 weeks. The percentage of hairs in the anagen growth phase increased during therapy. Three control patients, left untreated for 26 weeks, showed no significant improvement in hair density, meaningful density or the percentage of hair in the anagen growth phase. During CAT, each patient showed an increase in plasma SHBG and a fall in plasma testosterone levels. One patient with severe depressive symptom related to hair loss prior to therapy, returned to a normal way of life without the need for psychotropic drugs.